A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection

Summary

The purpose of this study is to evaluate the efficacy of rilematovir compared to placebo with respect to the time to resolution of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) symptoms.

Timeline

Start

2021-11-17

Primary completion

2022-03-31

Completion

2022-03-31

Outcome

Outcome not reported

Stopped (Business): “Janssen made the strategic decision to discontinue the PRIMROSE study. This decision is not based on any safety concerns.”

Drugs

Indications